PPARα/r dual agonists are also under development to treat more complex metabolic diseases, but some exhibit side effects and cause liver or cardiac dysfunction (Kim et al., 2019; Kalliora et al., 2019). This evidence concerns the gene PPARA and Other metabolic disease.